Toll Free: 1-888-928-9744

Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 34 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Pipeline Review, H1 2016', provides in depth analysis on Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted pipeline therapeutics. 

The report provides comprehensive information on the Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5)
- The report reviews Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Overview 6 Therapeutics Development 7 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Products under Development by Stage of Development 7 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Products under Development by Therapy Area 8 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Products under Development by Indication 9 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Products under Development by Companies 12 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Products under Development by Universities/Institutes 14 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 19 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Companies Involved in Therapeutics Development 20 Angion Biomedica Corp. 20 Merck & Co., Inc. 21 Novartis AG 22 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Drug Profiles 23 ANG-3586 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 CFG-920 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 osilodrostat phosphate - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Small Molecule to Inhibit CYP11B2 for Cardiovascular Disease - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Inhibit CYP17 and CYP11B2 for Prostate Cancer - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Small Molecules to Inhibit CYP19 and CYP11B2 for Cardiovascular Diseases - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Dormant Projects 31 Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or ALDOS or Aldosterone Synthesizing Enzyme or CYPXIB2 or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Discontinued Products 32 Appendix 33 Methodology 33 Coverage 33 Secondary Research 33 Primary Research 33 Expert Panel Validation 33 Contact Us 33 Disclaimer 34
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Action, H1 2016 17 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by Angion Biomedica Corp., H1 2016 20 Pipeline by Merck & Co., Inc., H1 2016 21 Pipeline by Novartis AG, H1 2016 22 Dormant Projects, H1 2016 31 Discontinued Products, H1 2016 32


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Mechanism of Actions, H1 2016 17 Number of Products by Stage and Routes of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 19

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving cream

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify